氨基嘧啶 c-Jun-N-端激酶（JNK）抑制剂的合成、生物评价、X 射线结构和药代动力学。
Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.
机构信息
Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way A2A, Jupiter, Florida 33458, USA.
出版信息
J Med Chem. 2010 Jan 14;53(1):419-31. doi: 10.1021/jm901351f.
Abstract
Given the significant body of data supporting an essential role for c-jun-N-terminal kinase (JNK) in neurodegenerative disorders, we set out to develop highly selective JNK inhibitors with good cell potency and good brain penetration properties. The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice. Microsomal stability in three species, P450 inhibition, inhibition of generation of reactive oxygen species (ROS), and pharmacokinetics in rats were also measured. Compounds 9g, 9i, 9j, and 9l had greater than 135-fold selectivity over p38, and cell-based IC(50) values < 100 nM. Moreover, compound 9l showed an IC(50) = 0.8 nM for inhibition of ROS and had good pharmacokinetic properties in rats along with a brain-to-plasma ratio of 0.75. These results suggest that biaryl substituted aminopyrimidines represented by compound 9l may serve as the first small molecule inhibitors to test efficacy of JNK inhibitors in neurodegenerative disorders.
摘要
鉴于 c-jun-N 末端激酶 (JNK) 在神经退行性疾病中具有重要作用的大量数据，我们着手开发具有良好细胞效力和良好脑穿透特性的高度选择性 JNK 抑制剂。利用生化和基于细胞的测定法评估了一系列氨基嘧啶的结构-活性关系 (SAR)，以测量 JNK 抑制和在小鼠中的脑穿透。还测量了三种物种中的微粒体稳定性、CYP450 抑制、活性氧 (ROS) 生成的抑制以及大鼠的药代动力学。化合物 9g、9i、9j 和 9l 对 p38 的选择性大于 135 倍，并且基于细胞的 IC50 值<100 nM。此外，化合物 9l 对 ROS 的抑制具有 IC50 = 0.8 nM，并且在大鼠中具有良好的药代动力学特性，脑-血浆比为 0.75。这些结果表明，以化合物 9l 为代表的二芳基取代的氨基嘧啶可能成为第一个小分子抑制剂，用于测试 JNK 抑制剂在神经退行性疾病中的疗效。
相似文献
1
Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.氨基嘧啶 c-Jun-N-端激酶（JNK）抑制剂的合成、生物评价、X 射线结构和药代动力学。
J Med Chem. 2010 Jan 14;53(1):419-31. doi: 10.1021/jm901351f.
2
Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.开发氨基嘧啶类 c-Jun N-末端激酶（JNK）抑制剂：激酶谱指导 1,2,3-苯并三唑先导化合物的优化。
Bioorg Med Chem Lett. 2013 Mar 1;23(5):1486-92. doi: 10.1016/j.bmcl.2012.12.047. Epub 2012 Dec 22.
3
Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties.开发吲哚/吲唑-氨基嘧啶作为 c-Jun N 端激酶（JNK）抑制剂：优化 JNK 效力和理化性质。
Bioorg Med Chem Lett. 2013 Jun 15;23(12):3565-9. doi: 10.1016/j.bmcl.2013.04.029. Epub 2013 Apr 21.
4
Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.新型c-Jun氨基末端激酶（JNK）抑制剂4-取代-2-氨基嘧啶的合成与构效关系研究
Bioorg Med Chem Lett. 2009 Apr 15;19(8):2099-102. doi: 10.1016/j.bmcl.2009.03.023. Epub 2009 Mar 13.
5
Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.合成和 SAR 研究 2-苯氧基吡啶作为新型 c-Jun N-端激酶抑制剂。
Bioorg Med Chem Lett. 2011 Dec 1;21(23):7072-5. doi: 10.1016/j.bmcl.2011.09.090. Epub 2011 Sep 29.
6
Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.合成和 SAR 研究 4-(吡唑-3-基)-吡啶作为新型 c-jun N-末端激酶抑制剂。
Bioorg Med Chem Lett. 2011 May 1;21(9):2732-5. doi: 10.1016/j.bmcl.2010.11.104. Epub 2010 Dec 1.
7
Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors.新型喹唑啉类化合物的合成及构效关系研究作为强效和可穿透血脑屏障的 c-jun N 末端激酶（JNK）抑制剂。
Bioorg Med Chem Lett. 2011 Mar 15;21(6):1719-23. doi: 10.1016/j.bmcl.2011.01.079. Epub 2011 Jan 22.
8
Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies.新型4-苯胺基嘧啶类强效c-Jun氨基末端激酶抑制剂的发现：合成及构效关系研究
Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. doi: 10.1016/j.bmcl.2006.10.093. Epub 2006 Nov 2.
9
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.作为淋巴细胞特异性激酶有效、选择性抑制剂的氨基嘧啶酰胺的结构导向设计：合成、构效关系及体内T细胞活化抑制
J Med Chem. 2008 Mar 27;51(6):1681-94. doi: 10.1021/jm7010996. Epub 2008 Mar 6.
10
Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.新型异恶唑的合成及构效关系研究作为有效的 c-jun N-末端激酶（JNK）抑制剂。
Bioorg Med Chem Lett. 2014 Jan 1;24(1):161-4. doi: 10.1016/j.bmcl.2013.11.052. Epub 2013 Dec 4.
引用本文的文献
1
The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia.小分子靶向 BCR-ABL 在慢性髓性白血病治疗中的进展。
Mini Rev Med Chem. 2024;24(6):642-663. doi: 10.2174/0113895575218335230926070130.
2
Discovery of Pyrimidine- and Coumarin-Linked Hybrid Molecules as Inducers of JNK Phosphorylation through ROS Generation in Breast Cancer Cells.嘧啶和香豆素连接的杂合分子通过 ROS 生成诱导乳腺癌细胞中 JNK 磷酸化的发现。
Molecules. 2023 Apr 13;28(8):3450. doi: 10.3390/molecules28083450.
3
A Highly Selective In Vitro JNK3 Inhibitor, FMU200, Restores Mitochondrial Membrane Potential and Reduces Oxidative Stress and Apoptosis in SH-SY5Y Cells.一种高选择性的体外 JNK3 抑制剂 FMU200，可恢复 SH-SY5Y 细胞的线粒体膜电位，减少氧化应激和细胞凋亡。
Int J Mol Sci. 2021 Apr 2;22(7):3701. doi: 10.3390/ijms22073701.
4
The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines.针对胆管癌细胞系的 EGFR 靶向化合物 3-[(4-苯基嘧啶-2-基)氨基]苯磺酰胺 (13f) 的作用。
Asian Pac J Cancer Prev. 2021 Feb 1;22(2):381-390. doi: 10.31557/APJCP.2021.22.2.381.
5
C-Jun N-terminal kinase inhibitors: Structural insight into kinase-inhibitor complexes.c-Jun氨基末端激酶抑制剂：激酶-抑制剂复合物的结构解析
Comput Struct Biotechnol J. 2020 Jun 12;18:1440-1457. doi: 10.1016/j.csbj.2020.06.013. eCollection 2020.
6
The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer.JNK 信号通路在炎症性皮肤疾病和癌症中的作用。
Cells. 2020 Apr 2;9(4):857. doi: 10.3390/cells9040857.
7
Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment.c-Jun N 端激酶（JNKs）在癫痫和代谢性认知功能障碍中的作用。
Int J Mol Sci. 2019 Dec 30;21(1):255. doi: 10.3390/ijms21010255.
8
In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases.深入分析激酶交叉筛选数据，以确定抑制Nek激酶家族的化学起始点。
Medchemcomm. 2017 Dec 8;9(1):44-66. doi: 10.1039/c7md00510e. eCollection 2018 Jan 1.
9
Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3.吡啶基咪唑支架的结构优化：将选择性从p38α丝裂原活化蛋白激酶转变为c-Jun氨基末端激酶3。
ACS Omega. 2018 Jul 31;3(7):7809-7831. doi: 10.1021/acsomega.8b00668. Epub 2018 Jul 12.
10
Pharmacological Inhibition of c-Jun N-terminal Kinase Reduces Food Intake and Sensitizes Leptin's Anorectic Signaling Actions.c-Jun N-末端激酶的药理学抑制可减少食物摄入并增强瘦素的厌食信号作用。
Sci Rep. 2017 Feb 6;7:41795. doi: 10.1038/srep41795.
本文引用的文献
1
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
An automated system to mount cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a small-scale robot.一种利用紧凑型样品盒和小型机器人将低温冷却的蛋白质晶体安装到同步加速器光束线上的自动化系统。
J Appl Crystallogr. 2002 Dec;35(6):720-726. doi: 10.1107/s0021889802016709.
3
JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosis.JNK3 在胰岛素分泌细胞中含量丰富，可防止细胞因子诱导的细胞凋亡。
Diabetologia. 2009 Sep;52(9):1871-80. doi: 10.1007/s00125-009-1431-7. Epub 2009 Jul 16.
4
Phaser crystallographic software.相位结晶学软件。
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. doi: 10.1107/S0021889807021206. Epub 2007 Jul 13.
5
Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.阻断c-Jun氨基末端激酶3（JNK3）的易位和激活可减轻帕金森病小鼠模型中的多巴胺能神经元损伤。
Neurochem Int. 2009 Jun;54(7):418-25. doi: 10.1016/j.neuint.2009.01.013. Epub 2009 Jan 29.
6
Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.新型c-Jun氨基末端激酶（JNK）抑制剂4-取代-2-氨基嘧啶的合成与构效关系研究
Bioorg Med Chem Lett. 2009 Apr 15;19(8):2099-102. doi: 10.1016/j.bmcl.2009.03.023. Epub 2009 Mar 13.
7
Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.描述氨基吡唑抑制剂对c-Jun氨基末端激酶3（JNK3）相对于p38的选择性的构效关系和X射线结构。
J Biol Chem. 2009 May 8;284(19):12853-61. doi: 10.1074/jbc.M809430200. Epub 2009 Mar 4.
8
Inhibitors of c-jun-N-terminal kinase (JNK).c-Jun氨基末端激酶（JNK）抑制剂
Mini Rev Med Chem. 2008 Jul;8(8):755-66. doi: 10.2174/138955708784912120.
9
Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.c-Jun氨基末端激酶3α1的动力学机制及抑制剂特性研究
Biochemistry. 2008 Mar 11;47(10):3076-84. doi: 10.1021/bi701852z. Epub 2008 Feb 13.
10
AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils.AS601245，一种c-Jun氨基末端激酶（JNK）抑制剂，可减轻沙鼠全脑缺血后的轴突/树突损伤和认知缺陷。
Br J Pharmacol. 2008 Jan;153(1):157-63. doi: 10.1038/sj.bjp.0707574. Epub 2007 Nov 19.
Zotero 插件